MX2018016419A - Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida. - Google Patents
Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.Info
- Publication number
- MX2018016419A MX2018016419A MX2018016419A MX2018016419A MX2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- substituted
- sulfonamide
- inhibitors
- kinase
- Prior art date
Links
- -1 N- (SUBSTITUTED-PHENYL) -SULFONAMIDE Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010089429 PERK kinase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 230000004906 unfolded protein response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de N-(sustituida-fenil)-sulfonamida, los cuales son extremadamente útiles como inhibidores de las proteínas quinasas (por ejemplo. quinasa PERK) y, en consecuencia, pueden ser empleadas para el tratamiento de desórdenes celulares proliferativos, como el cáncer, o enfermedades asociadas con vías de respuesta a proteinas desplegadas activadas, como la enfermedad de Alzheimer. La presente invención también proporciona métodos para preparar dichos compuestos, composiciones farmacéuticas que los comprenden, así como métodos para el tratamiento de enfermedades, utilizando dichas composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16175386 | 2016-06-21 | ||
| PCT/EP2017/064904 WO2017220477A1 (en) | 2016-06-21 | 2017-06-19 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018016419A true MX2018016419A (es) | 2019-09-09 |
| MX388660B MX388660B (es) | 2025-03-20 |
Family
ID=56148248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018016419A MX388660B (es) | 2016-06-21 | 2017-06-19 | DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10561660B2 (es) |
| EP (1) | EP3472165B1 (es) |
| JP (1) | JP6867417B2 (es) |
| KR (1) | KR102500416B1 (es) |
| CN (1) | CN109311894B (es) |
| AU (1) | AU2017279878B9 (es) |
| CA (1) | CA3029097A1 (es) |
| DK (1) | DK3472165T3 (es) |
| ES (1) | ES2964781T3 (es) |
| FI (1) | FI3472165T3 (es) |
| HU (1) | HUE064919T2 (es) |
| IL (1) | IL263739B (es) |
| MX (1) | MX388660B (es) |
| PL (1) | PL3472165T3 (es) |
| PT (1) | PT3472165T (es) |
| RU (1) | RU2753520C2 (es) |
| SI (1) | SI3472165T1 (es) |
| WO (1) | WO2017220477A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2753520C2 (ru) | 2016-06-21 | 2021-08-17 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы |
| WO2021030238A2 (en) * | 2019-08-09 | 2021-02-18 | Ohm Oncology | Method of synthesis of compound for dual inhibition of jak2 and bet |
| KR20210056827A (ko) * | 2019-11-11 | 2021-05-20 | 일동제약(주) | 신규한 벤젠설폰아미드 유도체 및 그의 용도 |
| EP4107146A1 (en) * | 2020-02-17 | 2022-12-28 | Alesta Therapeutics BV | Gcn2 modulator compounds |
| EP4146348B1 (en) | 2020-05-08 | 2024-07-03 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| CN111454261A (zh) * | 2020-05-27 | 2020-07-28 | 南京普锐达医药科技有限公司 | 一种4-氯吡咯并嘧啶化合物的合成方法 |
| AU2021381949A1 (en) | 2020-11-18 | 2023-06-15 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| WO2022212326A1 (en) | 2021-03-29 | 2022-10-06 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| EP4320127A1 (en) | 2021-04-05 | 2024-02-14 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| US20250000859A1 (en) | 2021-08-25 | 2025-01-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| JP2024544632A (ja) * | 2021-12-03 | 2024-12-03 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２及びｐｅｒｋキナーゼ阻害剤としての複素環式化合物 |
| EP4504720A1 (en) * | 2022-04-08 | 2025-02-12 | Alesta Therapeutics BV | Gcn2 modulator compounds |
| EP4491626A4 (en) * | 2022-06-08 | 2025-07-09 | Korea Res Inst Chemical Tech | PHENYLSULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER CONTAINING THEM AS ACTIVE INGREDIENT |
| WO2024249493A2 (en) * | 2023-05-30 | 2024-12-05 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase modulators and methods of use thereof |
| WO2025076441A1 (en) * | 2023-10-06 | 2025-04-10 | Alesta Therapeutics BV | Compounds of gcn2 modulators |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID24653A (id) * | 1997-03-19 | 2000-07-27 | Basf Ag | Zat-zat terapi |
| WO2000017202A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | 4-aminopyrrolopyrimidines as kinase inhibitors |
| GB0625827D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
| JP5819195B2 (ja) | 2008-10-16 | 2015-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
| UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| EP2909207A1 (en) * | 2012-10-16 | 2015-08-26 | Almirall S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| ES2638317T3 (es) | 2013-04-04 | 2017-10-19 | Janssen Pharmaceutica Nv | Nuevos derivados de N-(2,3-dihidro-1H-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina y N-(2,3-dihidro-1H-indol-5-il)-4-quinazolinamina como inhibidores de PERK |
| TW201533028A (zh) * | 2013-05-30 | 2015-09-01 | Plexxikon Inc | 用於激酶調節之化合物及其適應症 |
| JP2017507967A (ja) | 2014-03-11 | 2017-03-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤として作用する化合物 |
| RU2753520C2 (ru) * | 2016-06-21 | 2021-08-17 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы |
-
2017
- 2017-06-19 RU RU2019101002A patent/RU2753520C2/ru active
- 2017-06-19 KR KR1020197001839A patent/KR102500416B1/ko active Active
- 2017-06-19 US US16/312,061 patent/US10561660B2/en active Active
- 2017-06-19 CA CA3029097A patent/CA3029097A1/en active Pending
- 2017-06-19 FI FIEP17732075.1T patent/FI3472165T3/fi active
- 2017-06-19 HU HUE17732075A patent/HUE064919T2/hu unknown
- 2017-06-19 PL PL17732075.1T patent/PL3472165T3/pl unknown
- 2017-06-19 JP JP2018566910A patent/JP6867417B2/ja active Active
- 2017-06-19 SI SI201731456T patent/SI3472165T1/sl unknown
- 2017-06-19 PT PT177320751T patent/PT3472165T/pt unknown
- 2017-06-19 ES ES17732075T patent/ES2964781T3/es active Active
- 2017-06-19 CN CN201780038709.2A patent/CN109311894B/zh active Active
- 2017-06-19 AU AU2017279878A patent/AU2017279878B9/en active Active
- 2017-06-19 WO PCT/EP2017/064904 patent/WO2017220477A1/en not_active Ceased
- 2017-06-19 MX MX2018016419A patent/MX388660B/es unknown
- 2017-06-19 EP EP17732075.1A patent/EP3472165B1/en active Active
- 2017-06-19 DK DK17732075.1T patent/DK3472165T3/da active
-
2018
- 2018-12-16 IL IL263739A patent/IL263739B/en unknown
-
2019
- 2019-12-19 US US16/721,267 patent/US10918642B2/en active Active
-
2021
- 2021-01-04 US US17/140,471 patent/US11491158B2/en active Active
-
2022
- 2022-09-29 US US17/936,576 patent/US11833153B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018016419A (es) | Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida. | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
| CL2017002994A1 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| MX2018012609A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| CL2022000998A1 (es) | Inhibidores de las cinasas raf | |
| CR20190156A (es) | Derivados de bipirazol como inhibidores jak | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| MX391221B (es) | Compuestos y composiciones y usos de los mismos. | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| MX2021005822A (es) | Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteinas de los mismos para usarse como agonistas de lxr. | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| MX387785B (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos. |